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Abstract: Experiments using male CD1 mice were carried out to investigate the effects of 
subchronic (daily administration for 8 days) pretreatments with drugs enhancing GABAergic 
transmission (diazepam, 10 mg/kg, ip; gabapentin, 100 mg/kg, po; or vigabatrin, 500 mg/kg, po) 
on pentylenetetrazol (PTZ)-induced seizures, 24 h after the last injection. Subchronic admin-
istration of diazepam reduced latencies to clonus, tonic extension and death induced by PTZ. 
Subchronic vigabatrin produced enhanced latency to the ﬁ  rst clonus but faster occurrence of 
tonic extension and death induced by PTZ. Subchronic gabapentin did not modify PTZ-induced 
seizures. Autoradiography experiments revealed reduced benzodiazepine receptor binding in 
several brain areas after subchronic treatment with diazepam or gabapentin, whereas subchronic 
vigabatrin did not induce signiﬁ  cant receptor changes. The present results indicate differential 
effects induced by the subchronic administration of diazepam, vigabatrin, and gabapentin on 
the susceptibility to PTZ-induced seizures, benzodiazepine receptor binding, or both.
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Introduction
The increasing brain GABA (gamma-amino butyric acid) content and administration 
of centrally active GABA-mimetic agents have been used as an effective therapeutic 
approach for the treatment of epilepsy (Olsen and Avoli 1997). However, it has also 
been suggested that the use of drugs that continually alter synaptic transmission does 
not represent the best strategy to control seizure expression (Gale 1992). Prolonged 
administration of drugs enhancing GABA action can lead to reduced GABAergic 
function (Gyenes et al 1988) and alterations in GABAA receptors (Calkin and Barnes 
1994; Yu and Ticku 1995) as well as tolerance and dependence, especially to seda-
tive and anticonvulsant effects of drugs such as benzodiazepines (BDZ) (Braestrup 
et al 1979).
The increase of GABAergic transmission can induce excitatory effects (Gale 
1992). Chronic administration of BDZ can produce decreased sensitivity to GABA 
(Gallager et al 1984) and reduced ability of this amino acid to enhance BDZ binding 
(Brett and Pratt 1995). Indeed, withdrawal symptoms or spontaneous seizures have 
been reported to occur in nonepileptic BDZ abusers upon drug discontinuation (Lukas 
and Grifﬁ  th 1984).
The present study was designed to determine the effects of subchronic pre-
treatment with drugs enhancing GABAergic transmission on pentylenetetrazol 
(PTZ)-induced seizures and their correlation with BDZ receptor binding. We used 
vigabatrin, gabapentin, and diazepam because these are antiepileptic compounds Neuropsychiatric Disease and Treatment 2008:4(3) 620
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activating the GABAergic system. Vigabatrin is a GABA 
structural analogue, which irreversibly blocks GABA 
transaminase (GABA-T), the enzyme responsible of 
GABA degradation (Lippert et al 1977; Schechter et al 1979). 
The mechanisms of action of gabapentin, an analogue of 
GABA (Suman-Chauhan et al 1993), appear to be a complex 
synergy between increased GABA synthesis and function 
(Taylor et al 1998), non-NMDA receptor antagonism and 
binding to the α2δ-subunit of voltage dependent calcium 
channels. The latter action inhibits the release of excitatory 
neurotransmitters (Bennet and Simpson 2004). Diazepam, 
as a BDZ agonist, increases the channel opening frequency 
in presence of GABA increasing the effects of this amino 
acid (Haefely et al 1995). Autoradiography studies using 
[3H]ﬂ  unitrazepam were carried out to evaluate BDZ receptor 
binding in speciﬁ  c brain areas of mice treated subchronically 
with these antiepileptic drugs.
Material and methods
Animals
The experimental subjects were adult male CD-1 mice, 
weighing 25–30 g at the beginning of the experiments. Ani-
mals were housed in groups of 5–6 per cage (24 × 17 × 12 cm) 
under controlled environmental conditions (22 ± 1 °C; 12; 
12-h light–dark cycle, lighting at 8:00 h; food and water ad 
libitum). Experimental procedures were conducted accord-
ing to the Mexican Ofﬁ  cial Standard NOM-062-ZOO-1999 
and the Ethical Committee of the Center for Research and 
Advanced Studies (Mexico, Project 222/04).
Evaluation of PTZ-induced seizures
Mice received a daily administration of saline (0.1 ml/10 g, 
per oral [po] or intraperitoneal [ip]) for 1 week. This procedure 
allows the animals to habituate to manipulation, avoiding 
downregulation of BDZ binding induced by acute handling 
(Andrews et al 1992). Thereafter, they were daily treated with 
vigabatrin (500 mg/kg po, n = 10), gabapentin (100 mg/kg 
po, n = 10), or diazepm (10 mg/kg ip, n = 10) for 8 days. 
Immediately after each drug administration, animals were 
kept in individual cages for 30 min for behavioral evalua-
tion. Preliminary experiments from our group indicated that a 
single administration of diazepam, gabapentin, or vigabatrin, 
at the doses and routes described above, was able to reduce 
PTZ-induced seizures and Fos expression in the mouse brain. 
For the present study, we chose the oral route for gabapen-
tin and vigabatrin administration because it is how these 
drugs are used in patients. Indeed, vigabatrin exerts similar 
anticonvulsant potency at oral and ip administration (Loscher 
and Frey 1987). A solution of PTZ (Sigma Aldrich Ltd., St. 
Louis, MO, USA) freshly prepared was applied (90 mg/kg, 
ip) 24 h after the last drug administration. Latencies to the 
ﬁ  rst clonic seizure, tonic extension, and convulsion-induced 
death were evaluated during 30 min. The criterion of death 
was considered when animals spent 1 min or more with 
breathing and heart arrest. For each experimental drug, one 
control group (n = 10) was monitored in parallel. Control 
animals were manipulated as described above, except that they 
received daily saline administration instead of antiepileptic 
drugs. Diazepam was dissolved in vehicle (0.5% Tween 80 
and saline), whereas gabapentin, vigabatrin, and PTZ were 
dissolved in saline.
Evaluation of [3H]ﬂ  unitrazepam binding
After daily injection of saline (0.1 ml/10 g, po or ip) for 1 
week, mice received daily administration with vigabatrin, 
gabapentin, or diazepam for 8 days, at the doses and routes 
described above (n = 10 per drug). For each drug, a control 
group (n = 10) was monitored in parallel, in which animals 
received saline instead of antiepileptic drugs. Mice were sac-
riﬁ  ced by decapitation 24 h after the last administration and 
their brains were quickly removed, frozen in pulverized dry 
ice and stored at −70 °C. Frozen coronal sections of 20 µm 
were cut in a cryostat, thaw-mounted on gelatin-coated slides, 
and stored at −70 °C until the day of incubation.
Tris-HCl buffer (170 mM, pH 7.4) was used. Initially, 
brain sections were prewashed for 30 min at 25 °C. Then, 
brain sections were incubated during 45 min at 4 °C in a 
2 nM [3H]ﬂ  unitrazepam solution (88 Ci/mmol), in absence 
or presence of 1 µM of chlordiazepoxide. Binding obtained 
in presence of chlordiazepoxide was considered non-speciﬁ  c. 
Incubation was completed with 2 consecutive washes (1 min 
each) and a distilled water rinse (2 s) at 4 °C. The sections 
were then quickly dried under a gentle stream of cold air.
Slides were arrayed in X-ray cassettes with tritium stan-
dards (Amersham Biosciences, Piscataway, NJ, USA) and 
apposed to tritium-sensitive ﬁ  lm (Amersham Ultraﬁ  lm) for 
3 weeks at room temperature. Films were developed using 
standard Kodak D11 and ﬁ  xer. Optical densities were deter-
mined using a video-computer enhancement program (JAVA 
Jandel Video Analysis Software; Jandel Scientiﬁ  c, Corte. 
Madera, CA, USA). Brain regions were localized by reference 
to the mouse brain atlas of William and colleagues (1999). 
For each structure, 10 optical density readings were taken 
from at least 5 sections and they were averaged. The optical 
density readings of the standards were used to determine 
tissue radioactivity values (dpm/mm2) for the accompanying Neuropsychiatric Disease and Treatment 2008:4(3) 621
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tissue sections. Then, dpm/mm2 values were converted to 
fmol/mg protein by dividing dpm by the speciﬁ  c activity 
of [3H]ﬂ  unitrazepam (88 Ci/mmol) by 2.22. The value 2.22 
represents the conversion factor from Ci to dpm.
[3H]ﬂ  unitrazepam binding was analyzed in the following 
structures: motor, sensorimotor, and cingulate cortices; cau-
date putamen, nucleus accumbens, dentate gyrus, and CA1–3 
ﬁ  elds of hippocampus; medial, and basolateral amygdala 
nuclei; complete thalamus and hypothalamus.
Statistical analysis
The values obtained from PTZ-induced seizures and receptor 
binding were examined statistically by Student’s t tests.
Results
Saline group
All control animals (100%) pretreated with saline presented 
clonic seizures, and tonic extension after PTZ adminis-
tration. The incidence of death was from 60% to 80%. 
Latencies (mean ± SD) for these PTZ-induced changes 
were as follows: clonic seizures, 50 ± 4 s; tonic extension, 
527 ± 86 s; death, 636 ± 74 s (Figure 1). Concerning BDZ 
binding, [3H]ﬂ  unitrazepam binding was robust throughout 
the following evaluated brain areas: motor, sensorimotor, 
and cingulate cortices, dentate gyrus, CA1–3 fields of 
hippocampus, medial, and basolateral amygdala nuclei. 
[3H]ﬂ  unitrazepam binding was mild to moderate at the 
level of caudate putamen, nucleus acumbens, thalamus and 
hypothalamus (Tables 1–3).
Effects of subchronic administration
with diazepam
Mice pretreated subchronically with diazepam showed 
reduced latency to the first PTZ-induced clonus (21%, 
p  0.05), tonic extension (27%, p  0.05) and death (37%, 
p  0.05) (Figure 1). Mortality rate was similar to that found 
in the control group (80%).
Subchronic administration with diazepam induced 
a significant decrease of [3H]flunitrazepam bind-
ing in motor (25%, p  0.05), sensorimotor (27%, 
p  0.05) and cingulate (38%, p  0.05) cortices, dentate 
gyrus (33%, p  0.05), and CA1–3 ﬁ  elds of hippocampus 
(34%, p  0.05), medial (41%, p  0.05) and basolateral 
(40%, p  0.05) amygdala nuclei, and hypothalamus (35%, 
p  0.05) (Table 1).
Figure 1 Effects of subchronic administration with diazepam (upper panel), vigabatrin 
(medium panel) and gabapentin (lower panel) on PTZ-induced convulsions. Results 
show the latency in seconds from the injection of PTZ (90 mg/kg ip) to ﬁ  rst clonus, 
tonic extension and death.
Note: *p  0.05 when compared with control group.
Table 1 [3H]Flunitrazepam binding (fmol/mg of protein) in brain 
areas of mice treated with subchronic administration of saline and 
diazepam (10 mg/kg ip)
Brain area  Saline  Diazepam
Motor cortex  524.7 ± 27.5  382.6 ± 61.0*
Sensorimotor cortex  503.4 ± 35.2  367.6 ± 62.4*
Cingulate cortex  542.1 ± 30.1  334.4 ± 50.0*
Caudate putamen  199.2 ± 40.0  143.7 ± 8.4
Nucleus accumbens  253.8 ± 38.1  210.9 ± 34.9
CA1–CA3 ﬁ  elds  435.7 ± 57.1  286.1 ± 47.7*
Dentate gyrus  564.3 ± 62.1  378.5 ± 69.4*
Medial amygdala  552.7 ± 50.2  322.8 ± 56.6*
Basolateral amygdala  466.3 ± 60.6  276.3 ± 56.8*
Thalamus 290.6  ± 37.7  206.8 ± 34.7
Hypothalamus 431.5  ± 53.4  280.3 ± 57.3*
Notes: Each value represents the mean ± standard error; *p  0.05 compared with 
the saline group.Neuropsychiatric Disease and Treatment 2008:4(3) 622
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Effects of subchronic administration
with vigabatrin
Animals pretreated subchronically with vigabatrin presented 
enhanced latency to the ﬁ  rst clonus (32%, p  0.05), but 
shorter latencies for tonic extension (55%, p  0.05) and death 
(58%, p  0.05) (Figure 1). Mortality rate was not signiﬁ  cantly 
modiﬁ  ed (60%) when compared with control group (70%).
Subchronic administration with vigabatrin tended to 
decrease [3H]ﬂ  unitrazepam binding in motor (10%) and 
cingulate (6%) cortices; caudate putamen (18%) and nucleus 
accumbens (11%) (Table 2).
Effects of subchronic administration
with gabapentin
Mice treated subchronically with gabapentin did not show 
signiﬁ  cant changes in latency to the different components 
of PTZ-induced convulsions (Figure 1). However, their 
Table 2 [3H]Flunitrazepam binding (fmol/mg of protein) in brain 
areas of mice treated with subchronic administration of saline and 
vigabatrin (500 mg/kg po)
Brain area  Saline  Vigabatrin
Motor cortex  439.7 ± 52.4  398.9 ± 33.8
Sensorimotor cortex  360.3 ± 50.6  368.9 ± 38.3
Cingulate cortex  408.5 ± 51.5  386.6 ± 33.6
Caudate putamen  180.4 ± 21.9  147.4 ± 13.6
Nucleus accumbens  190.7 ± 26.6  168.6 ± 14.6
CA1–CA3 ﬁ  elds  292.1 ± 38.7  272.6 ± 23.0
Dentate gyrus  365.8 ± 43.2  351.5 ± 30.8
Medial amygdala  354.5 ± 46.2  379.8 ± 31.8
Basolateral amygdala  288.5 ± 29.4  295.1 ± 34.0
Thalamus 245.1  ± 31.5  277.8 ± 26.9
Hypothalamus 296.9  ± 36.4  292.6 ± 24.7
Notes: Each value represents the mean ± standard error.
Table 3 [3H]Flunitrazepam binding (fmol/mg of protein) in brain 
areas of mice treated with subchronic administration of saline and 
gabapentin (100 mg/kg po)
Brain area  Saline  Gabapentin
Motor cortex  505.5 ± 23.2  401.8 ± 30.4*
Sensorimotor cortex  503.1 ± 29.4  329.1 ± 37.7*
Cingulate cortex  501.5 ± 53.2  397.2 ± 33.0*
Caudate putamen  190.4 ± 21.3  173.9 ± 28.4
Nucleus accumbens  296.5 ± 28.3  218.9 ± 27.9
CA1–CA3 ﬁ  elds  480.7 ± 12.8  315.3 ± 33.5*
Dentate gyrus  535.7 ± 18.4  417.7 ± 29.8*
Medial amygdala  463.9 ± 50.7  338.0 ± 40.7*
Basolateral amygdala  458.8 ± 15.7  306.3 ± 32.67*
Thalamus 315.5  ± 55.2  172.6 ± 32.3*
Hypothalamus 389.1  ± 56.3  238.9 ± 49.6
Notes: Each value represents the mean ± standard error; *p  0.05 compared with 
the saline group.
mortality rate was lower (40%) when compared with control 
animals (60%).
Subchronic administration with gabapentin reduced 
[3H]ﬂ  unitrazepam binding in the motor (20%, p  0.05), 
sensorimotor (34%, p  0.05) and cingulate (20%, p  0.05) 
cortices; dentate gyrus (22%, p  0.05) and CA1–CA3 ﬁ  elds 
of hippocampus (34%, p  0.05), medial (27%, p  0.05) and 
basolateral (33%, p  0.05) amygdala nuclei, thalamus (45%, 
p  0.05) and hypothalamus (38%, p  0.05) (Table 3).
Discussion
There is growing awareness that antiepileptic drugs can 
sometimes worsen epileptic disorders (Perucca et al 1998) 
by disrupting the equilibrium between excitatory and 
inhibitory circuits (Loiseau 1998). In the present study, we 
found that mice pretreated subchronically with antiepileptic 
drugs enhancing GABAergic neurotransmission showed an 
augmented susceptibility to PTZ-induced seizures, reduced 
BDZ receptor binding, or both. These effects may be associ-
ated with a withdrawal-like syndrome as consequence of the 
sudden cessation of antiepileptic drugs.
PTZ is a noncompetitive GABA receptor antagonist that 
produces generalized seizures at high doses. The forebrain 
is involved in the expression of clonic seizures, whereas 
the activation of brainstem structures participates in the 
expression of the tonic component (Yonekawa et al 1980). 
We found that there is an aggravation of PTZ-induced sei-
zures following the repetitive administration of diazepam 
or vigabatrin. The shorter latency to all the components of 
the PTZ-induced seizures after subchronic administration 
with diazepam could result from a higher activation of 
forebrain areas, while the facilitation of the tonic extension 
component and mortality after subchronic treatment with 
vigabatrin could be restricted to an overactivation of brain-
stem areas. These results support previous studies indicating 
that the abrupt discontinuation of long-term use of BDZ 
may produce status epilepticus (Gatzonis et al 2000) and a 
higher seizure susceptibility to bicuculline (Gallager et al 
1985). Regarding vigabatrin, its repetitive administration 
leads to decreased electroconvulsive threshold (Loscher 
1982) and does not prevent the development of secondary 
spontaneous seizures as consequence of status epilepticus 
(Halonen et al 2001).
Diazepam produces its overt effects by interacting 
with a specific recognition site on GABAA receptors 
in the mammalian central nervous system. Diazepam 
enters brain rapidly, and is also cleared rapidly, yielding 
desmethyldiazepam and oxazepam as metabolites in Neuropsychiatric Disease and Treatment 2008:4(3) 623
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plasma and brain (Greenblatt and Sethy 1990). However, 
the repetitive daily injection of diazepam is associated 
with a peak concentration at 2 h after injection and a 
progressive drug accumulation in brain (Fernandes et al 
1999). This situation represents a marked ﬂ  uctuation in 
receptor occupancy by diazepam over a 24-h period that 
may induce a pharmacological kindling effect (Arnot et al 
2001), a critical condition for the higher susceptibility to 
PTZ-induced seizures observed in the present study.
The reduction in the BDZ receptor binding detected after 
the subchronic administration with diazepam is in agree-
ment with the results obtained from other authors in mouse 
brain (Rosenberg and Chiu 1979, 1981a, 1981b; Grimm and 
Hershkowitz 1981; Tietz et al 1986). Chronic treatment with 
diazepam has been shown to alter GABAA receptor afﬁ  nity 
for the agonist GABA and some BDZ binding characteristics 
(Tietz et al 1989; Wu et al 1994). Indeed, repetitive daily 
injection of diazepam decreases GABA enhancement of 
BDZ binding (Arnot et al 2001). These receptor changes 
could be involved in the lower BDZ binding and the higher 
vulnerability to PTZ-induced convulsions detected after the 
repetitive administration with diazepam.
The pharmacodynamic effects of vigabatrin (inhibition 
of central and peripheral GABA-T and increase of brain 
GABA levels) remain after the drug has been eliminated 
from plasma (Bolton et al 1989). However, when treatment 
is continued for 8 days, more marked effects of vigabatrin 
on GABA-T and GABA, a more severe toxicity and higher 
vigabatrin plasma concentrations are observed (Valdizán and 
Armijo 1992; Valdizán et al 1999), and tolerance developed 
to the anticonvulsant effect of the treatment (Loscher and 
Frey 1987). We found that the subchronic administration of 
vigabatrin did not modify the [3H]ﬂ  unitrazepam binding, a 
ﬁ  nding that is in agreement with others authors (Halonen 
et al 1991; Jackson et al 1994; Verhoeff et al 1999). 
Probably, the magnitude of the GABA level increase by 
vigabatrin is not sufﬁ  cient to induce changes in the BDZ 
receptor (Maloteaux et al 1987). However, subcronic treat-
ment with vigabatrin facilitated PTZ-induced seizures, an 
effect that could be explained by receptor desensitization 
or toxic effects. Indeed, in vigabatrin-treated animals, 
diazepam at high doses displayed lower anticonvulsant 
effects (Schmid et al 1996).
Gabapentin was originally developed as a chemical ana-
logue of GABA. However, different mechanisms are known 
to be involved in different therapeutic actions of this drug 
(Cheng and Chiou 2006). Its mechanisms of action appear to 
be a complex synergy between increased GABA synthesis, 
non-NMDA receptor antagonism and binding to the α2δ 
subunit of voltage dependent calcium channels. The latter 
action inhibits the release of excitatory neurotransmitters 
(Bennett and Simpson 2004). Gabapentin fails to inﬂ  uence 
GABA concentrations following both single and repeated 
administration in mice (Leach et al 1997), but increases 
aminooxyacetic acid-induced GABA accumulation in several 
brain regions (Loscher et al 1991). The plasma gabapentin 
half-life after oral administration in rodents is only about 2 h, 
and there is no evidence for accumulation of active metabo-
lites (Vollmer et al 1986). Gabapentin exerts potent anticon-
vulsant effect in rats after 2 h, but this effect is completely 
lost after 9 h (Loscher and Schmidt 1988). Our experiments 
revealed that subchronic administration with gabapentin 
did not modify the generalized seizures induced by PTZ, 
suggesting that its repetitive administration does not induce 
subsequent withdrawal-like effects.
It is known that the chronic exposition of an agonist 
produces an adaptation response that could be associated 
with receptor down-regulation or phosphorylation with a 
subsequent decrease in the response of involved system 
(Alberts et al 1994). These mechanisms could explain the 
decreased BDZ binding after the repetitive administration 
of antiepileptic drugs enhancing the GABAergic system. 
The differential effects on PTZ-induced seizures produced 
after subchronic diazepam, vigabatrin, and gabapentin may 
result from changes in speciﬁ  c subunits that regulate the 
GABAA or BDZ binding. For example, mutations in the γ2 
subunit may cause incorrect assembly of subunits with the 
receptor complex reducing sensitivity to BDZ, which would 
lead to an increase in neuronal excitability (Wu et al 2004). 
Similarly, deletion of GABAA receptor α1-subunit alters 
receptor subtype assembly, pharmacological and behavioral 
responses to BDZ (Kralic et al 2002). Concerning diazepam, 
its repetitive daily injection increases α1-subunit mRNA 
levels, an effect that may result in an increase in diazepam 
insensitive GABAA receptor subtypes (Arnot et al 2001). 
More experiments should be carried out to determine how 
the repetitive administration of antiepileptic drugs is associ-
ated with changes in GABAA receptor subunits leading to 
facilitation of seizure activity.
The mechanisms underlying the facilitation in seizure 
activity by antiepileptic drugs are poorly understood, but they 
may include the unmasking of secondary pharmacodynamic 
effects at high dosage or an undesired extension of the drug 
primary action to additional cell populations or neurotrans-
mitters. Studies support the interactions between GABA 
and cannabinoid systems (Pertwee et al 1988; Warnault Neuropsychiatric Disease and Treatment 2008:4(3) 624
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et al 2007). In fact, activation of presynaptic cannabinoid 
type 1 (CB1) receptors induces robust inhibition of local 
GABAergic afferents or depolarization-induced suppression 
of inhibition (DSI) (Wilson et al 2001; Wilson and Nicoll 
2001). It is possible that the abrupt cessation of GABAer-
gic drugs induces a withdrawal syndrome associated with 
sensitized GABAergic synapses to the presynaptic effect 
of cannabinoid CB1 receptor stimulation (Centonzene et al 
2007). This situation may facilitate the DSI and the reduced 
threshold to the PTZ-induced seizures.
Our results provide evidence of a relationship 
between subchronic exposition of an antiepileptic 
drug and the decrease in the BDZ receptor binding, a 
phenomenon that could be involved in the mechanisms of 
pharmacoresistant epilepsy (Aicardi 1998; Jallon 1997; 
Loscher et al 1997).
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